Evidence map›Paper›PMID 40186557›Full record

ArticleMicrobial biotechnology2025

Metabolic Engineering of a Serotonin Overproducing Saccharomyces cerevisiae Strain.

Andrés Planells-Cárcel, Elena Valera-García, Guillermo Quintas, José Luis Martínez, Sara Muñiz-Calvo, José Manuel Guillamón

Abstract read
In one paragraph

Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrés Planells-CárcelDepartmento de Biotecnología de Alimentos, Instituto de Agroquímica y Tecnología de Alimentos (IATA)-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.ORCID https://orcid.org/0000-0001-8942-3672
Elena Valera-GarcíaDepartmento de Biotecnología de Alimentos, Instituto de Agroquímica y Tecnología de Alimentos (IATA)-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.ORCID https://orcid.org/0009-0005-7105-1109
Guillermo QuintasLeitat Technological Centre, Health and Biomedicine, Barcelona, Spain.ORCID https://orcid.org/0000-0002-4240-9846
José Luis MartínezDepartment of Biotechnology and Biomedicine, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark.ORCID https://orcid.org/0000-0002-4490-8534
Sara Muñiz-CalvoDepartmento de Biotecnología de Alimentos, Instituto de Agroquímica y Tecnología de Alimentos (IATA)-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.ORCID https://orcid.org/0000-0003-4689-6589
José Manuel GuillamónDepartmento de Biotecnología de Alimentos, Instituto de Agroquímica y Tecnología de Alimentos (IATA)-Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain.ORCID https://orcid.org/0000-0001-5414-0787

Funding

Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana AGROALNEXT/2022/049FPU19/02060 grant funded by "ESF Investing in your future (MCIN/AEI/10.13039/501100011033)"MCIN/AEI/10.13039/501100011033 PID2022-142748OB-I00MCIN/AEI/10.13039/501100011033 TED2021-132386B-I00Spanish government MCIN/AEI to the IATA-CSIC as Center of Excellence (CEX2021-001189-S/MICIU/AEI/10.13039/501100011033)
6 · The paper itself

Abstract

The EU Green Deal prioritises the transformation of the chemical industry to a more environmentally sustainable model. This involves using microorganisms, such as Saccharomyces cerevisiae, to produce molecules more sustainably through biotechnological approaches. In this study, we demonstrate an example of serotonin production using S. cerevisiae as a cell factory, along with its optimisation and upscaling. To achieve this, we introduced two heterologous genes, the combination of tryptophan decarboxylase from Clostridium sporogenes (CsTDC) and tryptamine 5-hydroxylase from Oryza sativa (OsT5H), to complete the serotonin biosynthetic pathway using L-tryptophan (L-TRP) as a precursor. By modifying ARO4 to a feedback-resistant version (ARO4*), the flux of the shikimate pathway was significantly increased and serotonin production was achieved at levels up to 120 mg/L directly from the glucose source. After a medium optimisation, a final concentration of 80 g/L glucose and 300 mg/L of nitrogen resulted in better conditions for increasing serotonin titres. Using this medium in a 1 L bioreactor fermentation resulted in approximately 250 mg/L of serotonin. A targeted metabolomic study of the bioreactor growth medium identified potential bottlenecks in the serotonin-overproducing strain and future targets for increasing its titre. We have constructed a strain of S. cerevisiae that represents the first steps towards feasible industrial production of serotonin using a sustainable and environmentally friendly approach, paving the way for the development of similar biotechnological strategies in the future.

Indexed as

Metabolic EngineeringSaccharomyces cerevisiaeSerotoninAromatic-L-Amino-Acid DecarboxylasesBioreactorsBiosynthetic PathwaysClostridiumCulture MediaFermentationGlucoseOryzaRecombinant ProteinsTryptophanAromatic-L-Amino-Acid DecarboxylasesCulture MediaGlucoseRecombinant ProteinsSerotoninTryptophanbioreactormetabolic engineeringserotoninyeast

Identifiers

PMID40186557
PMCPMC11971721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.